Sponsor Pipeline

Innovent Biologics Technology Limited (Shanghai R&D Center) Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
6
Active Trials
4
Recruiting
1
Phase 3
1
Disease Areas
Active Trials by Phase
Phase 3
1
Phase 2
2
Phase 1
2
Early Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07414394 Tigulixostat (IBI128) vs Febuxostat in Gout Gout Recruiting
Phase 2
NCT07275840 A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD Neovascular Age-related Macular Degeneration Recruiting
NCT06908876 A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular… Diabetic Macular Oedema Active, Not Recruiting
Phase 1
NCT07160400 A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or… Part A: Healthy Part B: Overweight or Obesity Recruiting
NCT07170319 A Study of IBI3032 in Chinese Participants With Overweight or Obesity Overweight or Obesity Active, Not Recruiting
Early Phase 1
NCT07327632 This is a Multi-Center Study of IBI3026 in Participants With Locally Advanced… Solid Tumor Recruiting
Disease Areas
Obesity (2)
Get alerts when Innovent Biologics Technology Limited (Shanghai R&D Center)'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free